168018-40-4

Upstream product

• 168018-39-1 2-[3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-ylmethoxy]-isoindole-1,3-dione 
• 4377-41-7 2-Chloromethylquinoline 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 141863-12-9 ethyl 3-tert-butylthio-2-oxo-propionate 
• 168018-33-5 ethyl 5-methoxy-3-(t-butylthio)indole-2-carboxylate 
• 155143-15-0 ethyl 1-(4-chlorobenzyl)-3-(t-butylthio)-5-hydroxyindole-2-carboxylate 
• 168018-34-6 ethyl 1-(4-chlorobenzyl)-3-(t-butylthio)-5-methoxyindole-2-carboxylate 
• 168018-38-0 [3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-methanol 
• 168018-37-9 3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(quinolin-2-ylmethoxy)-1H-indole-2-carboxylic acid 
• 168018-35-7 3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(quinolin-2-ylmethoxy)-1H-indole-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis inhibitors

A series of substituted indolylalkoxyiminoalkylcarboxylates were found to be potent leukotriene biosynthesis inhibitors. The structure-activity relationships were investigated. Representative potent inhibitors identified were the quinolyl 3a (A-86885) and pyridyl 3b (A-86886) congeners with in vitro IC50s of 21 and 9 nM and in vivo leukotriene inhibition in the rat with oral ED50s of 0.9 and 1.7 mg/kg, respectively.